Use of metformin and vildagliptin fo treatment of type 2 diabetes in the elderly

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 811-817

  Sicras Mainar, Antoni ^a   Navarro Artieda, Ruth ^b  

^a Badalona Serveis Assistencials SA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Cardiovascular events; Diabetes; Health costs; Hypoglycemia; Metabolic control; Vildagliptin

Indexed keywords

GLITAZONE DERIVATIVE; METFORMIN; SULFONYLUREA; VILDAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT; NITRILE; PYRROLIDINE DERIVATIVE;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONTROLLED STUDY; DRUG RESPONSE; DRUG SAFETY; ELDERLY CARE; FEMALE; HEALTH CARE COST; HUMAN; HYPOGLYCEMIA; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PATIENT MONITORING; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; MULTICENTER STUDY;

ADAMANTANE; AGED; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; NITRILES; PYRROLIDINES; RETROSPECTIVE STUDIES;

EID: 84902952023     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S65327     Document Type: Article

References (32)

1. Working Group Diabetes Mellitus and Cardiovascular Disease of the Spanish Society of Diabetes. Diabetes mellitus and cardiovascular risk. Recommendations of the Working Group of Diabetes Mellitus and Cardiovascular Disease of the Spanish Diabetes Society 2009. Endocrinol Nutr. 2010;57:220-226.
2. Mata M, Antoñanzas F, Tafalla M, Sanz P. [The cost of type 2 diabetes in Spain. CODE-2 study]. Gac Sanit. 2002;16:511-520. Spanish.
3. González P, Faure E, Del Castillo A; Working Group for the Study of the Cost of Diabetes. [Cost of diabetes mellitus in Spain]. Med Clin (Barc). 2006;127:776-784. Spanish.
4. Rosado Martín J, Martínez López M.Á, Mantilla Morató T, et al. MAPA. [Prevalence of diabetes in an adult population in the region of Madrid (Spain). The Madrid Cardiovascular Risk study]. Gac Sanit. 2012;26:243-250. Spanish.
5. Soriguer F, Goday A, Bosch-Comas A, et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study. Diabetologia. 2012;55:88-93.
6. Menéndez Torre E, Lafita Tejedor J, Artola Menéndez S, et al. [Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes. Working Group for Consensus and Clinical Guidelines of the Spanish Diabetes Society]. Rev Clin Esp. 2011;211:147-155. Spanish.
7. Inzucchi S.E, Bergenstal R.M, Buse J.B, et al; American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-1379.
8. Puigdevall Gallego V, Laudo Pardos C, del Río Mayor M.J, Velasco Martín A. New drugs for the treatment of type-2 diabetes. Rev Clin Esp. 2000;200:151-156.
9. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
10. Nathan D.M, Buse J.B, Davidson M.B, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
11. Dejager S, Schweizer A, Foley JE. Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus. Vasc Health Risk Manag. 2012;8:339-348.
12. Cai L, Cai Y, Lu Z.J, Zhang Y, Liu P. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. J Clin Pharm Ther. 2012;37:386-398.
13. Lamberts H, Wood M, Hofmans-Okkes I.M, editors. The International Classification of Primary Care in the European Community. With a Multi-Language Layer. Oxford, UK: Oxford University Press; 1993.
14. World Health Organization. The Anatomical Therapeutic Chemical Classification System; Geneva, Switzerland: World Health Organisation; 1991.
15. Charlson M.E, Pompei P, Ales K.L, Mackenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
16. Weiner J.P, Starfield B.H, Steinwachs D.M, Mumford L.M. Development and application of a population-oriented measure of ambulatory care case-mix. Med Care. 1991;29:452-472.
17. Thompson S.G, Barber J.A. How should cost data in pragmatic randomised trials be analysed? BMJ. 2000;320:1197-1200.
18. Sinclair A, Morley J.E, Rodriguez-Mañas L, et al. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J Am Med Dir Assoc. 2012;13:497-502.
19. Halimi S, Raccah D, Schweizer A, Dejager S. Role of vildagliptin in managing type 2 diabetes mellitus in the elderly. Curr Med Res Opin. 2010;26:1647-1656.
20. Gaede P, Lund-Andersen H, Parving H.H, Pedersen O. Effect of a multifactorial intervention on mortality and in type 2 diabetes. N Engl J Med. 2008;358:580-591.
21. Márquez Contreras E, Martell Claros N, Gil Guillén V, et al; Compliance Working Group of the Association of Spanish Society of Hypertension and Spanish League for the Fight Against Arterial Hypertension (SEH-LELHA). [Therapeutic non-compliance with insulin in the treatment of diabetes mellitus 2]. Aten Primaria. 2012;44:74-81. Spanish.
22. Cramer J.A, Benedict A, Muszbek N, Keskinaslan A, Khan Z.M. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a
23. Jermendy G, Wittmann I, Nagy L, et al. Persistence of initial oral antidiabetic treatment in patients with type 2 diabetes mellitus. Med Sci Monit. 2012;18:CR72-CR77.
24. Guillausseau P.J. Impact of compliance with oral antihyperglycemic agents on health outcomes in type 2 diabetes mellitus: a focus on frequency of administration. Treat Endocrinol. 2005;4:167-175.
25. Scheen A.J. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab. 2012;38:89-101.
26. Breitscheidel L, Stamenitis S, Dippel F.W, Schöffski O. Economic impact of compliance to treatment with antidiabetes medication in type 2 diabetes mellitus: a review paper. J Med Econ. 2010;13:8-15.
27. Wild H. The economic rationale for adherence in the treatment of type 2 diabetes mellitus. Am J Manag Care. 2012;18(Suppl 3):S43-S48.
28. Liu S, Zhao Y, Hempe J.M, Fonseca V, Shi L. Economic burden of hypoglycaemia in patients with Type 2 diabetes. Expert Rev Pharmacoecon Outcomes Res. 2012;12:47-51.
29. Stamataros G, Schneider S.H. Vildagliptin in the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother. 2011;12:1967-1973.
30. Genovese S, Tedeschi D. Effects of vildagliptin/metformin therapy on patient-reported outcomes: work productivity, patient satisfaction, and resource utilization. Adv Ther. 2013;30:152-164.
31. Strain W.D, Lukashevich V, Kothny W, Hoellinger M.J, Paldánius P.M. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet. 2013;382:409-416.
32. Elisabeth Müller V, Schmacke N, Kolip P, Berger B. [Desirable, unfamiliar and in need of communication - the evidence-based decision aid of the Institute for Quality and Efficiency in Health Care (IQWiG)]. Z Evid Fortbild Qual Gesundhwes. 2012;106:290-294. German.